Medigen Vaccine Biologics Corporation (TPEX:6547)

Market Cap	11.72B -31.4%
Revenue (ttm)	594.96M -8.2%
Net Income	-165.64M
EPS	-0.50
Shares Out	328.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,000
Average Volume	2,686,897
Open	36.30
Previous Close	35.65
Day's Range	35.50 - 36.85
52-Week Range	33.50 - 56.60
Beta	0.71
RSI	41.91
Earnings Date	Mar 16, 2026

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2024, Medigen Vaccine Biologics's revenue was 605.64 million, an increase of 55.44% compared to the previous year's 389.62 million. Losses were -80.47 million, -93.06% less than in 2023.